Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK And HGS Face Off Over Buyout

This article was originally published in The Pink Sheet Daily

Executive Summary

Human Genome Sciences says the long-term blockbuster opportunity in Benlysta and the potential of its pipeline products are under-valued by GlaxoSmithKline’s takeover offer. Management at GSK, however, plays down any talk of increasing its bid.

You may also be interested in...



HGSI Gets Slightly Increased Buyout Bid, Accepts GSK Offer Of $3.6 Billion

After three months of battling, with lupus drug Benlysta still struggling, Human Genome Sciences accepted a modestly increased sales offer from partner GlaxoSmithKline.

Financings Of The Fortnight Parses Federal Funding For Roche/Genentech Alzheimer’s Candidate

Plus news on recent financing activity by Arena, OncoMed, Egalet and Dynavax.

Deals Of The Week: GSK/HGSI, Daiichi Sankyo/Coherus

GSK/Human Genome story takes a sharp turn, but does the big pharma’s hostile bid expose greater interest in cardiovascular drug darapladib than it is admitting?

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel